移植前赖氨酸（K）特异性甲基转移酶2A（）部分串联重复水平可预测单倍体相合供者造血干细胞移植后急性髓系白血病患者的复发情况。
Pre-transplantation levels of lysine (K)-specific methyltransferase 2A () partial tandem duplications can predict relapse of acute myeloid leukemia patients following haploidentical donor hematopoietic stem cell transplantation.
作者信息
Deng Dao-Xing, Ma Xiao-Hang, Wu Ze-Hua, Zhang Xiao-Hui, Xu Lan-Ping, Wang Yu, Yan Chen-Hua, Chen Huan, Chen Yu-Hong, Han Wei, Wang Feng-Rong, Wang Jing-Zhi, Huang Xiao-Jun, Zhao Xiao-Su, Mo Xiao-Dong
机构信息
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China.
出版信息
Blood Sci. 2024 Sep 25;6(4):e00207. doi: 10.1097/BS9.0000000000000207. eCollection 2024 Oct.
We aimed to identify dynamic changes of lysine (K)-specific methyltransferase 2A partial tandem duplications (-PTD) before and after haploidentical donor hematopoietic stem cell transplantation (HID HSCT) and explore the prognostic value of pre-transplantation levels of -PTD in acute myeloid leukemia (AML) receiving HID HSCT. Consecutive 64 AML patients with -PTD positivity at diagnosis receiving HID HSCT were included in this study. Patients with -PTD ≥1% before HSCT had a slower decrease of -PTD after HID HSCT. Patients with -PTD ≥1% before HID HSCT had a higher cumulative incidence of relapse (36.4%, 95% confidence interval [CI]: 6.3%-66.5%) at 2 years after HSCT than those with -PTD <1% (7.5%, 95% CI: 0.3%-14.7%, = .010). In multivariable analysis, -PTD ≥1% before HID HSCT was the only independent risk factor for relapse (hazard ratio [HR]: 4.90; 95% CI: 1.22-19.59; = .025). Thus, pre-transplantation levels of -PTD could predict relapse in AML patients following HID HSCT.
我们旨在确定单倍体相合供者造血干细胞移植（HID HSCT）前后赖氨酸（K）特异性甲基转移酶2A部分串联重复（-PTD）的动态变化，并探讨移植前-PTD水平对接受HID HSCT的急性髓系白血病（AML）患者的预后价值。本研究纳入了64例诊断时-PTD阳性且接受HID HSCT的连续AML患者。HSCT前-PTD≥1%的患者在HID HSCT后-PTD下降较慢。HID HSCT前-PTD≥1%的患者在HSCT后2年的累积复发率（36.4%，95%置信区间[CI]：6.3%-66.5%）高于-PTD<1%的患者（7.5%，95%CI：0.3%-14.7%，P = .010）。在多变量分析中，HID HSCT前-PTD≥1%是复发的唯一独立危险因素（风险比[HR]：4.90；95%CI：1.22-19.59；P = .025）。因此，移植前-PTD水平可预测接受HID HSCT的AML患者的复发情况。
Zotero 插件